Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) has been named to the National Association for Business Resources' 2020 list of Best and Brightest Companies to Work For in the Nation. Horizon is one of 151 winning organizations from across the United States out of 1,100 nominations. This year's award focuses on companies that have been able to pivot their workforces through COVID-19, along with being a leader on racial equity issues. “We're proud to be named one of the Best and

National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation

DraftKings

Cloudflare

Ceridian HCM Holding Inc.

Most experienced investors are well aware of the major indexes that compose the equity markets.

5 Stocks Set to Score From MSCI Index Rebalancing

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Tim Walbert, chairman, president and chief executive officer, has been honored with the 2020 RARE Champion of Hope Industry Partner award by Global Genes, a nonprofit organization that connects, empowers and inspires the rare disease community. Tim received the award at the virtual Global Genes Champions of Hope gala for his leadership in and dedication to the rare disease community, as well as his work advanc

Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala

Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.

Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator showed improved response rates as compared to KRYSTEXXA monotherapy. Reducing Immunogenicity of Pegloticase (RECIPE) demonstrated that 86.4 percent of patients (19 of 22) receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric aci

Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil

Horizon Therapeutics PLC (HZNP) CEO Timothy Walbert on Q3 2020 Results - Earnings Call Transcript

Horizon Therapeutics posted third-quarter earnings and sales that easily topped Wall Street expectations and the maker of drugs to treat rare diseases hiked its outlook, but HZNP stock fell. The post Horizon Therapeutics Easily Tops Views, Hikes Outlook, But HZNP Stock Falls appeared first on Investor's Business Daily.

Horizon Therapeutics Easily Tops Views, Hikes Outlook, But HZNP Stock Falls

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 74.00% and 13.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Surpasses Q3 Earnings and Revenue Estimates

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results and Increases Full-Year Net Sales and Adjusted EBITDA Guidance

Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Karin Rosén, M.D., Ph.D., has joined the company as executive vice president, research and development and chief scientific officer, reporting directly to Tim Walbert, chairman, president and chief executive officer. “We are thrilled to welcome Karin to Horizon during this transformative time in our company's growth,” said Walbert. “We have made significant progress during the last three years in building a st

Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune's Top Workplaces 2020, ranking number two out of other midsize companies in the Chicago area. “Receiving the Top Workplaces award is especially meaningful for us because the Chicago area is home to our U.S. headquarters,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “With a significant portion of our employees living and working in the

Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year

SEATTLE, Oct. 29, 2020 /PRNewswire/ -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon Therapeutics plc (Nasdaq: HZNP) is expanding to produce Horizon's Thyroid Eye Disease (TED)...

AGC Biologics and Horizon Therapeutics plc Expand Partnership

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in the Infusion Duration Study to Assess Tolerability of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate, or AGILE, clinical trial to evaluate a shorter infusion duration for KRYSTEXXA® (pegloticase injection) co-prescribed with methotrexate to treat people with chronic gout refractory to conventional therap

Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout

Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.

Horizon (HZNP) to Report Q3 Earnings: What's in the Cards?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW ). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. In this article, we will take a closer look at hedge fund sentiment towards Horizon Therapeutics Public Limited Company (NASDAQ:HZNP).

Were Hedge Funds Right About Crowding Into Horizon Therapeutics (HZNP)?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain's Chicago Business. Crain's compiles the list based on a review by independent intellectual property valuation firm, Ocean Tomo, which evaluates the patents produced each year by Chicago-area companies. Horizon made this year's list based on its work with its medicine used to treat urea cycle disorders (UCD), a rare genetic disorder

Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain's Chicago Business

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the top 100 adoption-friendly workplaces in the United States by the Dave Thomas Foundation for Adoption, ranking number 39 overall and number two in the pharmaceutical category. The list recognizes organizations with the most robust adoption benefit programs, comparing financial reimbursement and paid leave offered to employees who adopt, based on a survey of organizations across the

Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new research from the PROspective sTudy of pEglotiCase in Transplant patients (PROTECT) trial supporting the use of KRYSTEXXA (pegloticase injection) for people who are living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) and have undergone a kidney transplant. These data are being presented as part of this year's American Society of Nephrology (ASN) Ki

New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced that TEPEZZA® (teprotumumab-trbw) has been selected as a winner of the 19th Annual Chicago Innovation Award

Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE's Best Medium Workplaces 2020 list for the fifth consecutive year. Horizon ranked 10th out of 100 other medium-sized companies. “This recognition from FORTUNE and Great Place to Work is the result of our deep, ongoing efforts to elevate the Horizon experience for all our team members,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “We have worked ha

FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year

Is (HZNP) Outperforming Other Medical Stocks This Year?

Is Horizon Therapeutics Public Limited (HZNP) Outperforming Other Medical Stocks This Year?

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)

KRYSTEXXA, combined with the immunomodulator methotrexate, has been able to improve the response rate in patients with refractory gout.

Horizon Provides A Good Long-Term Value Biotech With FDA-Approved Krystexxa And Tepezza

Horizon Therapeutics: This Stock Has A 'Very Bullish' Rating By Both SA Quant Rating Tool And Wall Street Analysts

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that data from the investigator-initiated trial, REduCing Immunogenicity to PegloticasE (RECIPE), will be presented during ACR Convergence Nov. 5-9, 2020. Additional studies on the concomitant use of KRYSTEXXA (pegloticase injection) with an immunomodulator to optimize the treatment for people living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) will also be presented. “In

New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020

News for Horizon Pharma Stock (HZNP)